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Abstract
Background: Obtaining a suitable specimen for analysis in
a timely manner is pivotal in clinical chemistry service pro-
vision. Serum is recognized as the preferred specimen for
most assays, but because of time constraints for completion
of clotting and an increasing number of patients on anti-
coagulant therapy, latent clotting or no clotting is an outcome
which can lead to errors and delay in delivery of critical
results. Although lithium heparin plasma has unique pro-
blems, it has become an alternative in hospital-based
laboratories.
Methods: The Becton-Dickinson (BD) rapid serum tube
(RST) was evaluated in a hospital environment using a total
of 53 participants, both healthy and anticoagulated, for 31
analytes against BD PST II and BD SST II tubes measured
with Beckman DxC800 and DxI800 analyzers.
Results: Most results from the RST tube were comparable
with those from the SST II tube. Potassium results were clos-
er to the PST II plasma concentrations. Incomplete and latent
clotting was encountered in the RST specimens from partic-
ipants (cardiac and dialysis) who had received a total of
)7000 units of heparin wactivated partial thromboplastin
time (APTT) )150 sx, warfarin/heparin combination, and
specimens from cardiac surgery patients who had received a
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total of )25,000 units of heparin (APTT )200 s) at the
time of collection of specimens.
Conclusions: The RST tube provides a suitable alternative
to lithium heparin plasma tubes for most patients in a hos-
pital environment. However, latent clotting continued to
occur in specimens collected from participants who had
received high concentrations of anticoagulants.
Clin Chem Lab Med 2010;48:651–7.
Keywords: anticoagulants; latent clotting; plasma; rapid
serum tube; serum.
Introduction
Service quality encompasses total test error (impression and
inaccuracy), availability, cost, relevance and timeliness (1).
Delays in turn-around time (TAT) are the most common
complaint that laboratories receive from clinicians (2), and
as many as 87% of these complaints originate from Emer-
gency Department (ED) clinicians (3). This is understandable
because up to 80%–90% of medical decisions are based on
laboratory data (4–6). For laboratories to meet these expec-
tations, specimen quality and the time required to obtain a
suitable specimen (serum/plasma) for biochemical analysis
are key factors. Serum and heparinized plasma specimens
are considered equivalent for many assays, and it is not
uncommon for hospital-based laboratories to receive serum
or plasma specimens interchangeably for general chemistry
analysis. It is also well documented that there are significant
differences in the values for some analytes when measured
in serum or plasma, particularly potassium and total protein
(TP) (7–9), and these require different reference intervals.
Serum is considered fibrinogen-, fibrin- and cell-free under
optimal clotting conditions, and it is the preferred matrix
particularly for immunoassays. However, latent clot forma-
tion that occurs post-centrifugation can lead to risk of fibrin
clot interference on automated analyzers, especially those
with a common sample probe and no clot detection capacity
(10). The major advantage of lithium heparin plasma is that
it enables laboratories to achieve faster TATs. A number of
reports discuss some of the other major advantages (7, 8, 11)
and disadvantages (8, 12–16) of lithium heparin plasma.
Two recent studies by Chance et al. (17) and Giavarina et
al. (11), sponsored by Becton-Dickinson (BD), demonstrated
that plasma obtained with the BD Vacutainer PSTTM II
tubes can be used interchangeably with serum for most spe-
cial chemistry analytes and immunoassays performed on dif-
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ferent analytical platforms, permitting further consolidation
of test menus and use of single tubes for multiple tests. How-
ever, Giavarina et al. (11) found that lithium heparin plasma
could not be used for analysis of folate, testosterone, vitamin
B12, and progesterone with the Siemens Advia Centaur
analyzer (Siemens Healthcare Diagnostics, Medfield, MA,
USA). These findings were in agreement with findings
reported by Morovat et al. (18).
A new tube from BD Diagnostics, the BD Vacutainer
rapid serum tube (RST) is claimed to overcome the clotting
problems found with current commercial serum tubes. It con-
tains a thrombin-based clotting agent that can provide a clot-
ted specimen within 5 min following collection of blood
(19). This tube has been previously evaluated against the
serum separator tube (SST) using only healthy participants
and non-immunoassay analytes (20). The aim of this study
was to evaluate the BD Vacutainer RST in a tertiary hos-
pital setting against the BD Vacutainer PSTTM II lithium
heparin plasma and BD Vacutainer SSTTM II serum tubes
(BD Vacutainer Systems, Plymouth, UK) for both general
chemistry and immunoassay analytes. In addition, we wished
to determine if this is a suitable alternative to lithium heparin
plasma for rapid testing. The evaluation was performed by
recruiting both healthy individuals and participants receiving
different anticoagulants and concentrations of anticoagulants,
as routinely encountered in a tertiary referral hospital.
Materials and methods
The study was performed at the Princess Alexandra Hospital, Bris-
bane, Australia with appropriate ethics approval and with informed
consent from all participants. All 53 participants were adults
)18 years of age, with a mix of males and females. Of the 53
participants, 24 were healthy participants, three were outpatients on
low doses of warfarin, while the remaining 26 were inpatients. Of
the 26 inpatients, seven were undergoing cardiac surgery and had
received a total of 25–41,000 units of heparin at the time of blood
collection, which was performed within 30 min post heparin infu-
sion. The specimens were collected while participants were on
bypass. There were nine cardiac care unit participants recruited the
night before specimen collection receiving heparin by intravenous
(IV) infusion, 950–1450 units of heparin per hour. Seven remained
on IV heparin infusion (G12 h) at the time of specimen collection.
Two patients that were to undergo surgery had their infusion stopped
;3 h prior to specimen collection. From information obtained in
the patient record, the heparin concentration in the infusate and the
infusion rate were unchanged for the participants over this period.
The remaining inpatients were undergoing dialysis, eight were on
IV heparin infusion, and one on warfarin/heparin (;1750–
7000 units of heparin, initial bolus plus hourly top up doses), and
one on clexane. The specimens were collected at least 1 h following
the start of dialysis.
Blood was collected using a standardized draw order: citrate,
serum tubes (BD Vacutainer SSTTM II REF367954, 5.0 mL fill
volume and BD Vacutainer RST REF368771, 4.0 mL fill volume)
before the lithium heparin tube which contains 77 IU of heparin
(BD Vacutainer PSTTM II REF367375, 4.5 mL fill volume). Blood
was collected by venipuncture from healthy individuals and those
in the cardiac care unit. Collection was via the bypass port from
patients in cardiac surgery and via a blood line from dialysis par-
ticipants. The SST II tubes were allowed to clot for 30 min from
healthy participants and for 60 min for anticoagulated participants.
These tubes were visually inspected for clot formation prior to load-
ing in the centrifuge. The RST specimens were visually inspected
for clot formation at 5 min for all participants at the point of col-
lection (phlebotomy or clinical unit). The RST specimens from
healthy participants and anticoagulated participants that formed a
solid clot at 5 min were centrifuged as soon as they were delivered
to the laboratory (-20 min). If clotting was incomplete, the spec-
imens were rechecked every 10–15 min for clotting, and allowed
to clot for a maximum of 60 min. The lithium heparin specimens
were centrifuged immediately following delivery to the laboratory
(-20 min from collection).
All tubes were centrifuged at 3000 g for 10 min at 208C in a
swing bucket centrifuge, and then stored at ;218C. The tubes were
visually inspected for latent clotting immediately after centrifuga-
tion and then again just prior to loading onto the analyzers. The
primary tubes were used for analysis except in cases where latent
clotting was observed. In these cases, serum was transferred to an
aliquot tube, re-centrifuged to remove the clots, and the clean serum
transferred to another aliquot tube.
Analysis was performed using the Beckman DxC800 general
chemistry analyzer and a DxI800 immunoassay analyzer (Beckman
Coulter, Fullerton, CA, USA). Samples were loaded on the same
instruments at the same time and within 1–2 h post-centrifugation,
except in cases where recurrent latent clotting was encountered.
The upper limit of imprecision of the between-run coefficient of
variation (CVs) from two internal quality control samples for the
31 analytes tested on the Beckman DxC800 analyzers were as fol-
lows: -2% Naq, Kq, Cl–, urate, TP, albumin, creatinine kinase
(CK), total calcium (TCa), inorganic phosphorus (Pi); -3% glu-
cose, alkaline phosphatase (ALP), lactate dehydrogenase (LDH),
Mg2q, cholesterol, -4% HCO3–, urea, aspartate transaminase
(AST), triglycerides, high-density lipoprotein cholesterol (HDL-C),
transferrin (Trf); -5% creatinine; -6% g-glutamyltransferase
(GGT), Fe2q; -7% total bilirubin, alanine transaminase (ALT), C-
reactive protein (CRP), and lipase. A semiquantitative assessment
of hemolysis was also performed. For the DxI800 analyzer, the
CV% at three concentrations of quality control material was as fol-
lows: cortisol and thyroid stimulating hormone (TSH) -8%, free
thyroxine (fT4) -9%, and troponin I (TnI) ;16% at 0.052 mg/L,
and ;8% at 0.5 mg/L. We also measured the activated partial
thromboplastin time (APTT) using an ACTOPS (Instrumentation Lab-
oratory, Lexington MA, USA) as it was difficult to ascertain the
exact anticoagulant concentration in the participants’ blood at the
time of specimen collection in the cardiac care unit and for dialysis
participants.
The mean and standard deviation (SD) were calculated for each
test for the three tubes, and the percent difference between the
means of the three tubes. Exploratory analysis and frequency his-
tograms and tests of normality were performed to determine if para-
metric or non-parametric statistical tests would be used with the
Statistica V 6.0 software package (StatSoft, Tulsa, OH, USA). The
paired t-test was used for parametric data and the Wilcoxon
Matched-Pairs Rank test for non-parametric data to test for statis-
tical difference between analytes measured from the different tubes.
Results were considered statistically significant and analytically
important for p-0.05, and if the percent difference was greater than
the analyzers’ CV%. If a measurement was not obtained for an
analyte in any of the three tubes as a result of recurrent latent clot-
ting leading to insufficient specimen, insufficient specimen collect-
ed, analyte not requested on the analyzer, or insufficient reagent,
the result was not included in the calculation. Thus, there was var-
iability in the number of specimens analyzed per assay.
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Results
The blood from the 24 healthy and three participants on low
dose warfarin therapy clotted within 5 min in the SST and
RST tubes, forming a solid immobile clot, with no latent
clotting encountered. The SST and RST specimens from
the seven cardiac surgery participants that received
25,000–41,000 units of heparin had APPTs )200 s. The
SST sample did not clot at all, and no latent clotting was
visually observed or detected by the analyzers. With the RST
specimens, limited latent clotting was visually observed but
not detected by the analyzers. Blood specimens from the nine
participants in the cardiac care unit who had received
950–1450 units of heparin per hour took 20 min or longer
to form a visibly semi-solid or solid clot in the SST, and up
to 20 min in the RST specimens. When the APTT was
-60 s, no latent clotting was visually observed or detected
by the analyzers. Latent clotting was visually observed in
three specimens, but detected by the analyzers in two of the
RST specimens with an APTT )70 s. Similarly, the SST
specimens from the dialysis participants who received
3250–7000 units of heparin and who were also taking
100–150 mg salicylate daily, took 20 min or longer to form
a visibly semi-solid or solid clot. The RST specimens visibly
clotted within ;20 min. No latent clotting was visually
observed or detected by the analyzers in specimens with
-5000 units of heparin and APTT -150 s. Also, the one
participant on clexane 40 mg/4 h did not show latent clotting
and no clotting was detected by the analyzers. In contrast,
latent clotting was visually observed and detected by the ana-
lyzers in both SST and RST specimens in the two partici-
pants who received 6000–7000 units of heparin and had an
APTT )150 s. For the single participant receiving 6=4 mg/
day warfarin plus ;5000 units of heparin (APTT )150 s),
latent clotting was detected by the analyzers in the RST spec-
imen only. In one dialysis participant who received only
1750 units of heparin, the RST specimen visibly clotted in
;5 min, and the SST in ;30 min. No latent clotting was
encountered despite the fact that the APTT was )200 s.
Table 1 lists the analyte results determined in the three
different tubes, plasma separator tube (PST), SST and RST.
For the 31 analytes tested in the three tubes, there was gen-
erally good agreement in the concentrations determined, par-
ticularly between the SST and the RST. Differences that were
statistically significant and analytically important were:
a) RST vs. SST – LDH and TnI; b) RST vs. PST – Kq, Pi,
TP, LDH, ALP, HDL-C and TnI; and c) SST vs. PST – Kq,
Pi, TP, LDH, ALP, HDL-C and TnI. Results from the healthy
and groups receiving anticoagulants were analyzed separate-
ly for analytes showing statistical and analytical difference:
Kq, TP, LDH, Pi, ALP and HDL-C to demonstrate the
effects of incomplete clotting on the concentration of these
analytes (Table 2). The data confirmed that the Kq values
were closer to plasma values for the anticoagulated partici-
pants because of incomplete clotting, and decreased lysis of
cells that occurs during clotting. The means for LDH and
Kq were slightly lower in the RST tube compared with the
SST tube, perhaps due to faster clotting which minimizes
cell lysis and release of LDH and Kq. As expected, due to
removal of fibrinogen during the clotting process, the TP
results in the SST and RST were lower by 3.3%–4.7% com-
pared to results from the PST II. The TnI exceptions were
due to three false positive TnI results (one in PST plasma
and two in SST serum samples) (Table 3). When repeated,
the results matched those from the other tubes. No speci-
mens, irrespective of the tube type, showed significant
hemolysis, and all the hemolysis results were zero or one
(-0.5 g/L free hemoglobin). This magnitude of hemolysis
is very low and unlikely to influence clinically any of the
analyte determinations.
Discussion
This study evaluated the BD RST tube in a major tertiary
hospital with a very large cardiac and renal dialysis popu-
lation, where anticoagulated patients may be responsible for
up to 10% of all specimens received in the clinical chemistry
laboratory. The findings indicate that the use of this tube
represents an improvement over the current SST serum tube.
Visible clotting was achieved rapidly in RST specimens;
within ;5 min where participants had received a total of 0
to ;5000 units of heparin (APTT -150 s). However, the
RST and SST were ineffective for complete clotting of blood
specimens in a suitable time to be used interchangeably with
lithium heparin plasma (;15 min) from participants who
received a total of )7000 units of heparin (APTT )150 s).
This is approximately the time it takes specimens to get to
the laboratory and be accessioned for centrifugation in our
hospital. Latent clotting problems in the RST serum were
also encountered with cardiac and dialysis participants who
received a total of )7000 units of heparin (APTT )150 s),
and in a dialysis patient who had received 24 mg/day war-
farin in combination with heparin. No clotting or very min-
imal clotting of blood in RST specimens was observed in
cardiac surgery participants who received a total of more
than 25,000 units of heparin. Further, latent clotting was a
problem in some specimens. Therefore, use of the RST tube
would not be appropriate for specimens from patients receiv-
ing high doses ()7000 units) of heparin. The number of
such patients represents 1%–2% of all specimens received
in our clinical chemistry laboratory.
Differences in the concentrations of Kq, Pi and TP meas-
ured in lithium heparin plasma and serum are well estab-
lished and have been reported previously (7, 9). The SST
tubes showed smaller differences for Kq compared with hep-
arin plasma (5.4%; Table 1) compared with data reported in
literature, 7.1%–9.6% (9). The division of results into normal
and anticoagulated participant groups clearly demonstrated
that the variations in Kq concentrations for the normal group
is within published limits, 7.42% in the SST tube, but was
lower in the RST tube for both groups. This can be explained
by the failure of blood to clot in some of the anticoagulated
participants. These specimens effectively remained as plas-
ma, since platelets were not activated by the clotting process
to release Kq. The higher concentrations of Kq in serum are
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Table 3 Data from the false positive troponin (TnI) results.
Participant Original TnI result (repeat TnI result by analyzer reflex mode) mg/L
RST SST II PST II
18 (healthy participant) 0.000 0.053 (0.004) 0.000
20 (cardiac surgery participant on heparin) 0.004 0.013 0.093 (0.015)
38 (healthy participant) 0.004 1.334 (0.002) 0.006
The values in bold are the erroneous results.
also due to the contribution from lysis of red cells and leu-
kocytes, not just platelets. Serum specimens have slightly
higher levels of hemolysis compared with plasma (21). Inter-
mittently higher results can be obtained in plasma with Kq
or LDH or other analytes than in serum. However, repeat
results are lower than the original result. This is most likely
due to microclots containing cells that are aspirated and
release their contents during the analytical process or lead to
inaccuracies in analytical sampling volume (16). In this
study, not all Kq concentrations were lower in the plasma
specimen.
For TnI results, the specimens were automatically ana-
lyzed in duplicate using the analyzers’ reflex capability when
the first result was G0.04 mg/L (Table 3). Also, the results
were compared to those obtained in the other tubes. The
observed difference in the duplicates of the three specimens
were considered significant if they exceeded the recom-
mended change between patient samples ()3 SD for results
between G0.03–0.10 mg/L or )20% for results )0.10
mg/L) (22). This appears to be due to fibrin which may be
from latent clots, or incomplete removal during centrifuga-
tion. Fibrin has been implicated as the causative agent of
false positives in the Beckman AccuTnI assay (23). False
positive TnI results have been reported with the Beckman
AccuTnI assay for several years (23, 24), and most have
been detected by clinical staff rather than at the laboratory
level. Unlike our approach, performing analysis in duplicate
in order to identify discrepancies before reporting, recentri-
fugation of samples has been suggested if the reported result
is questioned by clinicians and thought to be false positive
(23) or recentrifuged automatically if it is above 0.1 mg/L
(24). These types of discrepancies clearly support the need
for a better specimen.
The results obtained here confirm that the BD RST tube
provides a suitable alternative to lithium heparin plasma for
most specimens collected in the hospital environment. How-
ever, latent clotting continued to occur in the RST specimens
when collected from participants receiving high doses of
anticoagulants (heparin or warfarin/heparin), even when
specimens were allowed to stand for 60 min prior to cen-
trifugation. Such latent clotting can compromise the accuracy
of results. It is evident from this and other studies that cur-
rently no single tube fulfills all the requirements for bio-
chemistry testing in all patients.
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